Microangiopathic hemolytic anemia natural history, complications and prognosis

	Microangiopathic hemolytic anemia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Microangiopathic hemolytic anemia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Microangiopathic hemolytic anemia natural history, complications and prognosis On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Microangiopathic hemolytic anemia natural history, complications and prognosis All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Microangiopathic hemolytic anemia natural history, complications and prognosis
on Microangiopathic hemolytic anemia natural history, complications and prognosis
Microangiopathic hemolytic anemia natural history, complications and prognosis in the news
Blogs on Microangiopathic hemolytic anemia natural history, complications and prognosis
Directions to Hospitals Treating Microangiopathic hemolytic anemia
Risk calculators and risk factors for Microangiopathic hemolytic anemia natural history, complications and prognosis

If left untreated, 90% of patients with [[[microangiopathic hemolytic anemia]] may die^[1].
The prognosis can be improved with prompt treatment. Therapeutic plasmapheresis reduces mortality rate to 20%^[1].
Common complications of microangiopathic hemolytic anemia include^[2]:
- acute renal failure with raised serum urea and creatinine levels
- intracranial hemorrhage as a consequence of severe thrombocytopenia
- myocardial infarction due to coronary artery occlusion

Reference

↑ ^1.0 ^1.1 Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC; et al. (1991). "Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group". N Engl J Med. 325 (6): 393–7. doi:10.1056/NEJM199108083250604. PMID 2062330.
↑ Scully, Marie; Hunt, Beverley J.; Benjamin, Sylvia; Liesner, Ri; Rose, Peter; Peyvandi, Flora; Cheung, Betty; Machin, Samuel J. (2012). "Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies". British Journal of Haematology. 158 (3): 323–335. doi:10.1111/j.1365-2141.2012.09167.x. ISSN 0007-1048.

Template:WH Template:WS

[pmid2062330-1] 1.0 ^1.1 Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC; et al. (1991). "Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group". N Engl J Med. 325 (6): 393–7. doi:10.1056/NEJM199108083250604. PMID 2062330.

[ScullyHunt2012-2] Scully, Marie; Hunt, Beverley J.; Benjamin, Sylvia; Liesner, Ri; Rose, Peter; Peyvandi, Flora; Cheung, Betty; Machin, Samuel J. (2012). "Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies". British Journal of Haematology. 158 (3): 323–335. doi:10.1111/j.1365-2141.2012.09167.x. ISSN 0007-1048.

[1]

[2]

Microangiopathic hemolytic anemia natural history, complications and prognosis

Reference

Navigation menu